HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, announced today that the Company has entered into an Exclusive Distribution Agreement with Akron Biotech ("Akron"), a leading manufacturer of ancillary materials and a contract development and manufacturing organization for the cell, gene therapy, and regenerative medicine industries, for the commercialization of HCW11-006 for use as a reagent to support a new method of producing highly functional human CAR-T cells for treating cancer, autoimmune disease, and infectious diseases. Akron operates within a highly specialized global network of biomedical institutions, primarily catering to a customer base of advanced therapy developers, biopharmaceutical companies, and research organizations. Akron manufactures and markets cGMP-compliant ancillary materials (such as cytokines, media supplements, and plasmid DNA) necessary for bringing regenerative medicine from preclinical stages to commercialization.